A US study to evaluate transarterial radioembolization (TARE) in combination with durvalumab and bevacizumab therapy in people with unresectable hepatocellular carcinoma amenable to TARE - EMERALD-Y90

Exclusion Criteria

• -Disease amenable to curative surgery or transplantation or curative ablation.
• -Participants co-infected with HBV and HDV
• -Any history of nephrotic or nephritic syndrome.
• -Clinically significant (eg, active) cardiovascular disease
• -Participants with uncontrolled hypertension
• -History of hepatic encephalopathy
• -Known hereditary predisposition to bleeding or thrombosis; any prior or current evidence of bleeding diathesis.
• -Receipt of more than 1 prior embolization (TACE or TARE) treatment/procedure
• - Participant has received any prior anticancer systemic therapy for unresectable HCC.
• -History of arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to enrollment.
• -History of abdominal fistula or gastrointestinal (GI) perforation, non-healed gastric ulcer that is refractory to treatment, or active GI bleeding within 6 months prior to enrollment